Journal article · 2025 · Open access

Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023)

Matthew Ward, Niamh M. O’Boyle

RSC Medicinal Chemistry, 16(10), 4540–4570 · Published 1 January 2025 · DOI 10.1039/d5md00403a

Free PDFView at the publisherCite this paper

In brief

“Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023)” is a 2025 journal article by Matthew Ward and Niamh M. O’Boyle, published in RSC Medicinal Chemistry. OpenAlex counts 68 citations as of 15 November 2026, which puts it in the top 5% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at RSC Medicinal Chemistry.

Citations
68
Most cited in
2026 (65)
Field-weighted impact
19.46
References
21
Authors
2

Abstract

This review presents a detailed analysis of the heterocycle diversity amongst medicines with new active substances (NAS) approved by the European Medicines Agency (EMA) in the 10 years from 2014-2023. A total of 380 medicines were approved that contain a NAS, of which 160 are small molecule products that contained one or more NAS with a heterocycle (164 NAS in total). Of the 164 heterocycle-containing NAS, 76% contained more than one heterocycle. The majority (59%) of the 164 active substances contained at least one fused heterocycle. The most common bicyclic rings were quinoline, benzimidazole, indole, and pyrrolopyrimidine. Tricyclic and polycyclic fused rings were observed but were rare. There were 28 distinct monocyclic heterocycles, consisting of 3, 4, 5, and 6 membered rings. 5-Membered rings were the most diverse as 15 of the 28 heterocycles are 5-membered rings. 6-Membered rings ranked second with 12 heterocycles. There was one 3-membered ring and one 4-membered ring seen. Nitrogen was by far the most common heteroatom in both monocyclic and fused heterocycles. Oxygen, sulfur and boron appeared in monocyclic heterocycles, whilst oxygen, sulfur and phosphorous were noted in fused heterocycles. The most common monocyclic heterocycles were pyridine, piperidine, pyrrolidine, piperazine, pyrimidine, pyrazole, triazole, imidazole and tetrahydropyran. This analysis provides valuable information on the structural diversity of heterocycles that were present in EMA approved medicines between 2014-2023. It highlights heterocycle occurrences, diversity, substitution patterns, and trends. The information detailed will be of interest to organic chemists, researchers, regulatory agencies, and the pharmaceutical industry as it demonstrates how common heterocycles are seen amongst EMA approved medicines for a wide range of therapeutic areas.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ward, M., & O’Boyle, N. M. (2025). Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023). RSC Medicinal Chemistry, 16(10), 4540–4570. https://doi.org/10.1039/d5md00403a

MLA 9

Ward, Matthew, and Niamh M. O’Boyle. “Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023).” RSC Medicinal Chemistry, vol. 16, no. 10, 2025, pp. 4540–4570. https://doi.org/10.1039/d5md00403a.

Chicago

Ward, Matthew and Niamh M. O’Boyle. 2025. “Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023).” RSC Medicinal Chemistry 16 (10): 4540–4570. https://doi.org/10.1039/d5md00403a.

Harvard

Ward, M. and O’Boyle, N. M. (2025) ‘Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023)’, RSC Medicinal Chemistry, 16(10), pp. 4540–4570. doi:10.1039/d5md00403a.

IEEE

M. Ward and N. M. O’Boyle, “Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023),” RSC Medicinal Chemistry, vol. 16, no. 10, pp. 4540–4570, 2025, doi: 10.1039/d5md00403a.

BibTeX

@article{ward2025analysis,
  title     = {{Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023)}},
  author    = {Ward, Matthew and O’Boyle, Niamh M.},
  journal   = {RSC Medicinal Chemistry},
  year      = {2025},
  volume    = {16},
  number    = {10},
  pages     = {4540--4570},
  doi       = {10.1039/d5md00403a},
  url       = {https://doi.org/10.1039/d5md00403a}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • heterocyclic compounds
  • structural diversity
  • new active substances
  • European Medicines Agency approval
  • pharmaceuticals
  • fused heterocycles
  • quinoline
  • benzimidazole

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Ward, M., & O’Boyle, N. M. (2025). Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014–2023). RSC Medicinal Chemistry, 16(10), 4540–4570. https://doi.org/10.1039/d5md00403a

How many times has this paper been cited?

68 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at RSC Medicinal Chemistry.

Who wrote this paper?

Matthew Ward, Niamh M. O’Boyle.

What is the DOI of this paper?

10.1039/d5md00403a. The permanent link is https://doi.org/10.1039/d5md00403a.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.